Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800089 | 0.84 | CYP19A1 (0.43) | CYP19A1CYP3A4CYP1A2 | |
| SCHEMBL800784 | 0.83 | ALDH1A1 (0.49) | CYP19A1 | |
| SCHEMBL800506 | 0.82 | NPC1 (0.42) | — | |
| SCHEMBL800077 | 0.81 | HTT (0.54) | CYP3A4 | |
| SCHEMBL800118 | 0.78 | CA2 (0.52) | ESR1ESR2CYP3A4TAAR1 | |
| SCHEMBL800616 | 0.77 | TBXAS1 (0.68) | LTA4H | |
| SCHEMBL800484 | 0.76 | CYP3A4 (0.58) | CYP3A4CYP1A2 | |
| SCHEMBL926518 | 0.76 | LTA4H (0.58) | LTA4HITGB3ITGA2BTAAR1 | |
| SCHEMBL10193658 | 0.76 | LTA4H (0.44) | LTA4HITGB3ITGA2BCYP19A1TAAR1 | |
| SCHEMBL800076 | 0.76 | PLA2G10 (0.45) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9115079-B2 | NDM inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| US-20140221330-A1 | NDM INHIBITOR | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | LTA4H 803/4885ITGB3 4794/4885ITGA2B 3950/4885 |
| US-20140221330-A1 | NDM INHIBITOR | MGAM, NQO1, NQO2 | LTA4H 639/4885ITGB3 4710/4885ITGA2B 4281/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | LTA4H 842/4885ITGB3 4801/4885ITGA2B 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.